ALNYLAM PHARMACEUTICALS INCALNYLAM PHARMACEUTICALS INCALNYLAM PHARMACEUTICALS INC

ALNYLAM PHARMACEUTICALS INC

No trades
See on Supercharts

DUL fundamentals

ALNYLAM PHARMACEUTICALS INC revenue breakdown overview

ALNYLAM PHARMACEUTICALS INC revenue for the last year amounted to 1.66 B EUR, the most of which — 1.66 B EUR — came from its highest performing source at the moment, Ribonucleic Acid Interference Therapeutics, the year earlier bringing 969.32 M EUR. The greatest contribution to the revenue figure was made by United States — last year it brought ALNYLAM PHARMACEUTICALS INC 1.16 B EUR, and the year before that — 575.30 M EUR.

By source
By country